GlassScriptPhysician profile
Michael J Davanzo
NPI 1285864991
$1,673.28
in general payments reported to CMS, 2019-2025
19 companies · $1,491 in 2025
The $1,491 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $10.66 · 2023: $17.74 · 2024: $153 · 2025: $1,491.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,663.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,662.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $398.15 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $239.05 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $208.88 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $138.06 | 2025 | Xifaxan |
| Tolmar, INC. | $125.57 | 2025 | Jatenzo |
| Glaxosmithkline, LLC. | $79.10 | 2024-2025 | Trelegy Ellipta |
| Amgen INC. | $76.83 | 2023-2025 | Otezla, Repatha, Otezla |
| Lilly USA, LLC | $62.06 | 2024-2025 | Jardiance, Mounjaro, Zepbound |
| Axsome Therapeutics, INC. | $59.70 | 2025 | Auvelity |
| Exact Sciences Corporation | $54.27 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Otsuka America Pharmaceutical, INC. | $45.10 | 2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $43.50 | 2025 | Caplyta |
| Corcept Therapeutics | $35.41 | 2025 | Korlym |
| Actelion Pharmaceuticals US, INC. | $25.66 | 2025 | Opsumit, Uptravi |
| Phathom Pharmaceuticals, INC. | $23.36 | 2025 | Voquezna |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.59 | 2025 | Jardiance |
| Kowa Pharmaceuticals America, INC. | $14.60 | 2025 | Zoryve |
| Pfizer INC. | $13.73 | 2025 | |
| Genentech USA, INC. | $10.66 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Davanzo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.